Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking gene-therapy progress across hundreds of pages can feel overwhelming, especially when Amicus Therapeutics packs each report with dense clinical data, orphan-drug milestones, and complex risk factors. If you have ever searched for “Amicus Therapeutics insider trading Form 4 transactions” or wondered where the Fabry trial costs sit in the latest 10-Q, you know the challenge.
Stock Titan solves it. Our AI reads every Amicus Therapeutics quarterly earnings report 10-Q filing, parses R&D expense lines, and links them to pipeline stages—turning raw numbers into plain-English insights. Receive real-time alerts the moment a director files a “Amicus Therapeutics Form 4 insider transactions real-time” notice. Need context? Our summaries place each disclosure next to prior periods so you instantly see trends. From the Amicus Therapeutics annual report 10-K simplified that explains cash runway, to an “Amicus Therapeutics 8-K material events explained” note covering fresh FDA guidance, every document is indexed, searchable, and annotated.
Use cases include: spotting executive stock sales via “Amicus Therapeutics executive stock transactions Form 4”; comparing quarter-over-quarter revenue with our “Amicus Therapeutics earnings report filing analysis”; or reviewing “Amicus Therapeutics proxy statement executive compensation” to gauge incentive alignment. Whether you are understanding Amicus Therapeutics SEC documents with AI for the first time or maintaining a hedge-fund model, our platform delivers complete, up-to-the-minute coverage—no biomedical PhD required.
Amicus Therapeutics (FOLD) reported an insider transaction by its Chief People Officer. On 11/04/2025, the officer sold 25,643 shares of common stock at a $9.5098 weighted-average price (range $9.50–$9.54).
Following the sale, the officer beneficially owns 322,618 shares, held directly. The transactions were effected under a Rule 10b5-1 trading plan adopted on March 14, 2025.
Amicus Therapeutics reported stronger Q3 2025 results. Net product sales were $169.1 million, up from $141.5 million. The company posted net income of $17.3 million versus a loss a year ago. For the first nine months, sales reached $449.0 million and net loss narrowed to $28.8 million.
Galafold generated $371.5 million in year-to-date revenue, while Pombiliti + Opfolda contributed $77.5 million. Gross profit for the first nine months was $402.6 million. Operating cash flow was $16.9 million for the period. Cash, cash equivalents, and marketable securities totaled $263.8 million as of September 30, 2025.
Long-term debt carrying value was $392.0 million on a $400.0 million senior secured term loan due 2029. Inventory increased to $177.9 million to support commercial growth. The company recorded a $30 million upfront R&D expense tied to a U.S. license for Dimerix’s DMX-200. Shares outstanding were 308,533,548 as of October 24, 2025.
Amicus Therapeutics (FOLD) furnished an update on its recent performance, announcing financial results for the quarter ended September 30, 2025. The company issued a press release and will host a conference call and webcast on November 4, 2025 to discuss third‑quarter results.
The materials were provided under Item 2.02 and are furnished, not filed. Attached exhibits include the press release (Exhibit 99.1) and conference call presentation materials (Exhibit 99.2).
Amicus Therapeutics (FOLD) insider transaction: Simon N.R. Harford, identified as Chief Financial Officer and reporting person, reported a sale of 12,529 shares of Amicus common stock on 08/21/2025 at a reported price of $7.60 per share. After this transaction he is reported to beneficially own 214,898 shares. The Form 4 is signed by an attorney-in-fact on 08/25/2025.
Perceptive Advisors and related parties report a 2.4% shared ownership stake in Amicus Therapeutics (FOLD). The filing shows Perceptive Life Sciences Master Fund, Ltd. directly holds 7,412,830 shares and Perceptive Advisors LLC, as manager, and Joseph Edelman, as managing member, report shared voting and dispositive power over those shares. No sole voting or dispositive power is claimed. The ownership percentage is calculated using 308,239,374 shares outstanding. The filing states the position is not held to influence control of the company.
FAQ
What is the current stock price of Amicus Therapeut (FOLD)?
What is the market cap of Amicus Therapeut (FOLD)?
